TNGX’s vopimetostat PRMT5 inhibitor expands into lung and brain tumors
TNGX said vopimetostat, a PRMT5 inhibitor, is advancing toward approval and expanding beyond pancreatic cancer into lung cancer and glioblastoma, with additional data updates expected at ESMO.
Vopimetostat, a PRMT5 inhibitor, has shown unprecedented response rates in pancreatic cancer and is advancing toward approval, with upcoming data updates expected at ESMO. Expansion plans include lung cancer and glioblastoma, supported by strong financial resources and global regulatory strategies…